Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer

详细信息    查看全文

• 作者：Hongxi Wu^a ; ¹ ; Lulu Zhang^b ; ¹ ; Xiaofang Gao^a ; Xiuna Zhang^a ; Jingjing Duan^a ; Linjun You^a ; Yan Cheng^a ; Jinsong Bian^c ; Qingyi Zhu^d ; ^{zhuqy1971@126.com} ; Yong Yang^a ; ^{yy@cpu.edu.cn}
• 关键词：Sorafenib ; Enzalutamide ; Castration-resistant prostate cancer ; Androgen receptor ; Tyrosine kinase
• 刊名：Cancer Letters
• 出版年：2017
• 出版时间：28 January 2017
• 年：2017
• 卷：385
• 期：Complete
• 页码：108-116
• 全文大小：2292 K
• 卷排序：385

文摘

Sorafenib and enzalutamide synergistically inhibited the development of CRPC. The combination could exert a synergistic inhibitory on both AR and ERK pathway. Sorafenib may prevent the development of enzalutamide resistance in CRPC patients.